Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
MBRX
MBRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MBRX News
U.S. Stocks Close Lower, Dow Jones Falls Over 300 Points
Feb 19 2026
Benzinga
U.S. Stocks Open Lower with Dow Down Over 250 Points
Feb 19 2026
Benzinga
Moleculin Biotech Exercises Warrants for $8.3M
Feb 19 2026
seekingalpha
Moleculin Biotech Reports Significant Progress
Feb 18 2026
stocktwits
Moleculin Biotech Reports Progress in Annamycin Clinical Trial
Feb 18 2026
Newsfilter
Moleculin Biotech Inc. Announces 40% Preliminary CRC Rate in Miracle Trial
Feb 18 2026
moomoo
Moleculin Launches CEO Corner Platform for Investor Insights
Feb 13 2026
Newsfilter
Moleculin Biotech's 2026 MIRACLE Trial Data Unblinding Expected
Jan 12 2026
Globenewswire
Moleculin Stock Falls 17% Despite Encouraging Phase 1 WP1066 Results for Pediatric Brain Tumors
Dec 17 2025
NASDAQ.COM
Moleculin's WP1066 Demonstrates Immune Response and Positive Safety Profile in Pediatric Brain Cancer Study
Dec 17 2025
NASDAQ.COM
Moleculin Biotech Increases Enrollment to 78% for MIRACLE Trial
Dec 09 2025
Globenewswire
Moleculin Biotech Increases Enrollment to 78% for MIRACLE Trial
Dec 09 2025
Newsfilter
Moleculin Biotech to Showcase Company Overview in Virtual Investor Closing Bell Series
Nov 28 2025
NASDAQ.COM
Moleculin Biotech CEO to Host Investor Webcast on December 2, 2025
Nov 26 2025
Newsfilter
Moleculin Biotech Announces 1-for-25 Reverse Stock Split, Reducing Outstanding Shares to 2.1 Million
Nov 26 2025
Newsfilter
Moleculin Biotech Executes 1-for-25 Reverse Stock Split, Reducing Shares to 2.1 Million
Nov 26 2025
Globenewswire
Show More News
